Drug Profile
Urocanic acid - Herantis Pharma
Alternative Names: Ci-UCA Emulsion Cream; Cis-UCA; Cis-UCA Eye Drops; ProtoCure; UCA-001; UCA-002Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator BioCis Pharma
- Developer Herantis Pharma
- Class Acrylates; Antineoplastics; Imidazoles; Immunotherapies; Skin disorder therapies; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Atopic dermatitis; Dry eyes
Highest Development Phases
- Phase II Dry eyes
- Suspended Atopic dermatitis
- No development reported Bladder cancer; Interstitial cystitis
- Discontinued Plaque psoriasis
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Dry-eyes(In volunteers) in Finland (Ophthalmic, Drops)
- 07 Feb 2017 Phase-II development for Dry eyes is ongoing in USA (Ophthalmic, drops)
- 12 Oct 2015 Urocanic acid - Herantis Pharma is available for licensing-http://herantis.com/wp-content/uploads/2015/09/Herantis_NLS_2015.pdf